Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis

Area of Science:

• Clinical diagnostics
• Medical testing
• Parasitology

Background:

• Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic condition affecting red blood cells.
• Screening for G6PD deficiency is vital for managing diseases like malaria.
• Antimalarial drugs such as primaquine and tafenoquine require careful administration in G6PD deficient individuals.

Purpose of the Study:

• To evaluate the diagnostic performance of the STANDARD G6PD Test.
• To assess the test's utility in guiding malaria treatment decisions.
• To determine the test's accuracy across diverse populations and specimen types.

Main Methods:

• Pooled data from clinical studies across multiple countries (Bangladesh, Brazil, Ethiopia, India, Thailand, UK, US).
• Retrospective analysis of capillary and venous specimens using the STANDARD G6PD Test.
• Comparison with spectrophotometry for G6PD activity and HemoCue/CBC for hemoglobin measurement.

Main Results:

• High sensitivity (100%) for G6PD deficient cases (<30% activity) and 77% for intermediate cases in capillary specimens.
• High specificity (98.1% for deficient, 92.8% for intermediate females).
• 100% sensitivity for G6PD deficient and intermediate cases in 396 P. vivax malaria cases.
• Over 95% of cases would receive correct primaquine treatment; over 87% correct tafenoquine treatment.

Conclusions:

• The STANDARD G6PD Test facilitates safe access to essential antimalarial drugs.
• The test demonstrates strong performance for identifying G6PD deficiency, informing treatment strategies.
• Operational factors will influence the adoption and implementation of this diagnostic tool.